Loading
A phase 2 trial of [68Ga]BED003 in colorectal cancer, ovarian cancer, gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Blue Earth Diagnostics, now recruiting.
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications is a phase 2 interventional study registered as NCT07702292 by Blue Earth Diagnostics, with 71 participants planned, started 2026-06-30 and due to reach its primary completion in 2028-02. Interventions recorded: [68Ga]BED003.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Blue Earth Diagnostics (Bracco), Medpace, Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.
Shares Medpace, Ovarian cancer, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Blue Earth Diagnostics (Bracco) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/